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Summary
B-1a and B-1b lymphocytes were found to exhibit
specialized roles in providing immunity to Strepto-
coccus pneumoniae and differ dramatically in their
developmental requirements. Transgenic mice over-
expressing CD19 (hCD19Tg) generated B-1a cells and
natural antibodies that provided protection during in-
fection, while CD19-deficient (CD19−/−) mice lacked
B-1a cells, lacked natural antibodies, and were more
susceptible to infection. By contrast, pneumococcal
polysaccharide (PPS) immunization protected CD19−/−
mice during lethal challenge, whereas hCD19Tg mice
remained unprotected. This resulted from differences
in the B-1b subset: the key population found to pro-
duce protective PPS-specific antibody in both wild-
type and CD19−/− mice. Thus, CD19−/− mice generated
B-1b cells and protective adaptive PPS-specific anti-
body responses, whereas hCD19Tg mice lacked B-1b
cells and adaptive PPS-specific antibody responses.
This reciprocal contribution of B-1a and B-1b subsets
to innate and acquired immunity reveals an unex-
pected division of labor within the B-1 compartment
that is normally balanced by their coordinated devel-
opment.
Introduction
B-1 lymphocytes represent a unique B cell population
distinguished from conventional B (B-2) cells by their
phenotype, anatomical localization, self-renewing ca-
pacity, and production of natural antibodies (Berland
and Wortis, 2002; Hardy and Hayakawa, 2001). B-1
cells have an IgMhiIgDloCD23−B220lo phenotype, with
Mac-1 expression on peritoneal but not splenic B-1
cells. B-1 cells are subdivided into the B-1a (CD5+) and
B-1b (CD5−) subsets based on cell surface CD5 expres-
sion. The origins of B-1 cells and whether B-1a and
B-1b cells are derived from the same or distinct pro-
genitor cells are unknown, although B-1a cell develop-
ment is strongly influenced by B cell antigen receptor
(BCR) specificity and strength of signaling. Mice defi-
cient in critical intracellular BCR signaling molecules,
including B cell linker protein, Bruton’s tyrosine kinase,
Vav, phospholipase Cγ2, phosphatidylinositol 3-kinase
p85, and protein kinase C, exhibit dramatic reductions
in the B-1a cell compartment (Berland and Wortis,
2002; Hardy and Hayakawa, 2001). As a key regulator
of B cell signaling, CD19 also plays a prominent role in*Correspondence: thomas.tedder@duke.eduB-1 cell development. CD19 deficiency impairs B-1a
cell development (Engel et al., 1995; Rickert et al.,
1995), while CD19 overexpression augments B-1a cell
development (Sato et al., 1996). Although BCR and
CD19 signaling regulate B-1a cell development, the rel-
ative importance of signaling strength to B-1b cell de-
velopment is unknown.
B-1 cells are envisioned as key players in the early
humoral response against pathogens and are thought
to be the primary antibody producers in response to T
cell-independent type 2 (TI-2) antigens along with mar-
ginal zone (MZ) B cells (Martin and Kearney, 2000; Mar-
tin et al., 2001). TI-2 antigens are characterized by high
molecular weight, repeating epitopes, and slow de-
gradability in vivo. These antigens, such as bacterial
capsular polysaccharides, elicit rapid antibody responses
by multivalent BCR crosslinking in the absence of major
histocompatibility complex class II-restricted T cell help
(Mond et al., 1995). Intact responses to TI-2 antigens
are critical for the generation of protective immunity to
encaspulated extracellular bacteria such as Strepto-
coccus pneumoniae, a gram-positive bacteria that is
the predominant cause of otitis media, community-
acquired pneumonia, septicemia, and meningitis in hu-
mans (Wuorimaa and Kayhty, 2002). Preexisting natural
antibodies provide innate protection against these
types of bacterial infections in naive hosts (Briles et al.,
1981; Mi et al., 2000). Immunization-induced antibodies
specific for the TI-2 antigen, pneumococcal polysac-
charide (PPS), also contribute substantially to protec-
tive immune responses against S. pneumoniae (Wuori-
maa and Kayhty, 2002). As such, the Pneumovax
vaccine consists of 23 types of PPS, including pneumo-
coccal polysaccharide type 3 (PPS-3), which elicits
specific protection against serotype 3 S. pneumoniae,
a major cause of invasive pneumococcal disease (Ort-
qvist, 2001; Wuorimaa and Kayhty, 2002). Impaired PPS
responses (Amsbaugh et al., 1972) and inadequate pro-
duction of natural antibodies important for protection
against encapsulated bacteria (Briles et al., 1981) result
from defects in B cell signaling pathways, such as
those caused by the xid mutation. However, the effects
of alterations in CD19 expression or CD19-regulated
signaling pathways on protective antibody responses
to encapsulated bacteria are largely unknown. Further-
more, relatively little is known about the functional con-
tributions of individual B-1a and B-1b subsets despite
the proposed importance of B-1 cells in generating pro-
tective antibody responses against bacterial antigens.
In this study, the importance of B-1 cell subsets in
protection against S. pneumoniae infection was exam-
ined using CD19-deficient (CD19−/−) and CD19-overex-
pressing (hCD19Tg) mice. B cells from CD19−/− mice
are hyporesponsive to transmembrane signals, and
CD19−/− mice generate modest immune responses to T
cell-dependent (TD) antigens with impaired natural anti-
body production (Engel et al., 1995; Rickert et al., 1995;
Sato et al., 1995, 1996, 1997). By contrast, B cells from
hCD19Tg mice are hyperresponsive to mitogens, such
as LPS, and hCD19Tg mice generate elevated TD hu-
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aautoantibody production (Engel et al., 1995; Inaoki et
al., 1997; Sato et al., 1995, 1996, 1997; Zhou et al.,
1994). The present study demonstrates that B-1b cells N
Care the predominant B-1 cell subset in CD19−/− mice,
while B-1a cells develop preferentially in hCD19Tg T
Cmice. The reciprocal regulation of B-1a and B-1b devel-
opment dramatically alters the abilities of CD19−/− and t
fhCD19Tg mice to generate protective humoral re-
sponses to S. pneumoniae. This shift in B-1 cell sub- e
Ssets revealed that wild-type B-1a cells spontaneously
cproduce natural antibodies important for early protec-
Ltion, while wild-type B-1b cells are the primary source
oof adaptive antibody responses to PPS during infection





CD19 Deficiency Increases Susceptibility l
to S. pneumoniae Infection s
The importance of CD19 expression during acute infec- m
tion was assessed by comparing the susceptibility of d
CD19−/−, wild-type, and hCD19Tg mice to S. pneumo- C
niae infection. Mice were infected with 10, 102, or 103 T
colony forming units (cfu) of WU2, an encapsulated b
type 3 strain of S. pneumoniae. hCD19Tg and wild-type t
mice were equally susceptible to S. pneumoniae, with
102 cfu causing >50% lethality (Figure 1A). By contrast, P
CD19−/− mice were more susceptible to S. pneumoniae h
infection, with only 10 cfu causing >50% mortality and TFigure 1. Increased Susceptibility of CD19−/−,
but Not hCD19Tg, Mice to S. pneumoniae In-
fection Due to Impaired Natural Antibody
Production
(A) Survival of CD19−/−, wild-type (WT), and
hCD19Tg mice following infection with 10,
102, or 103 cfu S. pneumoniae. Each graph
represents results from 5–10 mice of each
genotype.
(B–D) S. pneumoniae-specific natural serum
antibody (B), PPS-3-specific IgM (C), and
PC-specific IgM (D) titers in CD19−/−, WT,
and hCD19Tg mice were determined by
ELISA using 3-fold serial dilutions, beginning
with 1:10 (B and D) or 1:25 (C) dilutions. Val-
ues represent mean (±SEM) reciprocal titers
from 4–7 mice of each genotype. Individual
titers for CD19−/− and WT mouse sera are
shown in (B) (right panel). Asterisks repre-
sent significant differences between wild-
type and other sample means; p < 0.01.
(E) WT mouse serum protects CD19−/− mice
against infection. CD19−/− mice were given
500 l of WT (n=21), CD19−/− (n = 24), or
Rag1−/− (n = 7) mouse serum i.p. or no serum
(n = 8) 2 hr before challenge with w60 cfu of
S. pneumoniae. Results represent data
pooled from three experiments, with chi-
square analysis for group comparisons indi-
cated.102 cfu resulting in 100% mortality. Thus, CD19 expres-ion contributes significantly to host defense against
cute S. pneumoniae infection.
atural Antibody Production Requires
D19 Expression
o determine whether the enhanced susceptibility of
D19−/− mice to S. pneumoniae infection was due to
he absence of protective natural antibodies, serum
rom naive CD19−/−, wild-type, and hCD19Tg mice was
xamined. Serum antibody titers to whole heat-killed
. pneumoniae were >20-fold lower in CD19−/− mice
ompared to wild-type and hCD19Tg mice (Figure 1B).
ikewise, CD19−/− mouse sera did not react with PPS-3
r phosphocholine (PC) in contrast with sera from
CD19Tg and wild-type mice (Figures 1C and 1D). In
act, no significant differences were detected in the re-
ctivity of CD19−/− and Rag1−/− mouse sera with whole
acteria or PC (data not shown). However, transferring
ild-type mouse serum into CD19−/− mice before chal-
enge with S. pneumoniae significantly increased their
urvival compared to mice given serum from CD19−/−
ice (Figure 1E). Moreover, there was no significant
ifference in survival between CD19−/− mice given
D19−/− mouse serum and Rag1−/− mouse serum.
hus, CD19 deficiency severely impairs natural anti-
ody production, which provides the first level of pro-
ection during S. pneumoniae infection.
PS-3 Immunization Protects CD19−/−, but Not
CD19Tg, Mice against Infection
he importance of CD19 expression during acquiredhumoral immune responses to PPS-3 was assessed.
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sera of CD19−/− mice, but was detectable in sera from
hCD19Tg and wild-type mice (Figures 1C and 2A). PPS-
3-specific IgG3 was not detected in naive CD19−/−,
wild-type, or hCD19Tg mice. However, PPS-3 immuni-
zation resulted in equal or higher IgM and IgG3 anti-
body responses in CD19−/− mice than in wild-type mice.
By contrast, PPS-3-specific IgM antibody responses
were significantly lower in hCD19Tg mice. The absence
of measurable PPS-3-specific IgG3 antibodies in hCD19Tg
mice after immunization was even more striking. Thus,
CD19 expression was not required for normal PPS-3-
specific antibody responses following immunization,
while CD19 overexpression inhibited PPS-3 antibody
responses.
Whether PPS-3 immunization affected susceptibility to
S. pneumoniae was assessed by challenging CD19−/−,
wild-type, and hCD19Tg mice with 103 or 104 cfu of
bacteria 14 days following immunization. CD19−/− and
wild-type mice were equally protected against these
normally lethal doses of S. pneumoniae (Figure 2B). ByFigure 2. PPS-3 Immunization Elicits Protection in CD19−/−, but Not
hCD19Tg, Mice during S. pneumoniae Challenge
(A) PPS-3-specific antibody responses of CD19−/−, wild-type (WT),
and hCD19Tg mice. PPS-3-specific titers were determined by
ELISA using 3-fold serial dilutions beginning at 1:25. Significant dif-
ferences between mean (±SEM) titers are indicated by asterisks;
*p < 0.05 (n R 5 mice/genotype).
(B) Fourteen days following PPS-3 immunization (as in [A]), 6–8
mice of each genotype were infected with 103 or 104 cfu of S. pneu-
moniae.contrast, hCD19Tg mice were significantly more sus-ceptible to infection than wild-type mice (p < 0.05, 103
cfu challenge; p < 0.001, 104 cfu challenge). In fact, im-
munization did not dramatically enhance the survival of
hCD19Tg mice (Figure 2B) when compared with naive
hCD19Tg mice (Figure 1A; 103 cfu dose). Thus, altered
CD19 expression clearly influenced protective humoral
responses following PPS-3 immunization, but in an un-
expected way.
CD19−/− and hCD19Tg Mice Respond Differently
to S. pneumoniae Immunization
Whether humoral responses to whole bacteria differed
from responses to purified PPS-3 was assessed follow-
ing immunization of CD19−/−, wild-type, and hCD19Tg
mice with whole heat-killed WU2 bacteria. CD19−/− and
wild-type mice generated comparable PPS-3-specific
IgM and IgG3 antibody responses (Figure 3A). By con-
trast, hCD19Tg mice did not produce PPS-3-specific
antibodies, but did generate appreciable levels of bac-
teria-specific antibody (Figures 3A and 3B). S. pneu-
moniae-specific antibody titers were >1:1000 in wild-
type mice when assessed by flow cytometry (day 14,
Figure 3B). Sera from CD19−/− and hCD19Tg mice also
reacted with whole bacteria, but with titers of w1:100.
However, the addition of PPS-3 to the sera inhibited
wild-type and CD19−/− serum antibodies from binding
to bacteria, but did not diminish the binding of serum
antibodies from hCD19Tg mice (Figure 3C). Thus,
CD19−/− mice responded optimally to PPS-3, while
wild-type mice responded optimally to both PPS-3 and
non-PPS-3 antigens. By contrast, PPS-3-specific anti-
body generation was impaired in hCD19Tg mice, al-
though hCD19Tg mice generated humoral immune re-
sponses to other S. pneumoniae antigens.
The isotypes of bacteria-specific antibodies pro-
duced by CD19−/− and hCD19Tg mice were also clearly
different following whole bacteria immunizations. Wild-
type mice produced the highest levels of each antibody
isotype (Figure 3D), potentially reflecting optimal anti-
body responses to both TI and TD antigens. By con-
trast, CD19−/− mice produced substantial IgG3 anti-
bacterial antibody responses, but IgG1 responses were
not detectable. hCD19Tg mice produced substantial
IgG1 anti-bacterial antibody responses, but no detecta-
ble IgG3 responses. CD19−/− mice produced higher IgM
and IgG2a levels than hCD19Tg mice, while IgG2b
levels were similar between CD19−/− and hCD19Tg
mice. These results suggest clear differences in the
types of bacterial antigens that CD19−/− and hCD19Tg
mice respond to.
Antibody responses to PC, a hapten displayed on the
cell wall polysaccharide of S. pneumoniae, were also
assessed following immunizations with whole heat-
killed bacteria. Natural anti-PC IgM titers were high in
hCD19Tg mice relative to wild-type mice, whereas PC-
specific IgM antibodies were absent in CD19−/− mice
(Figure 3E). Following bacteria immunizations, wild-
type mice produced high IgM and IgG3 anti-PC titers.
In comparison, PC-specific IgM titers were reduced
5-fold in hCD19Tg mice and R70-fold in CD19−/− mice
7 days post immunization. Moreover, PC-specific IgG3
responses were not detectable in hCD19Tg or CD19−/−
mice. Thus, alterations in CD19 expression had distinct
effects on humoral immune responses to different bac-
terial antigens, including PC and PPS-3.
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10Figure 3. S. pneumoniae Immunization Induces Antibody Responses in CD19−/−, Wild-Type, and hCD19Tg Mice that Provide Differing Degrees
of Protection during Infection
(A) PPS-3-specific antibody responses in mice immunized with heat-killed S. pneumoniae. Antibody titers were determined by ELISA using
3-fold serial dilutions beginning at 1:100. Significant differences between mean (±SEM) titers are indicated by asterisks; *p < 0.05 (nR 5 mice
per genotype).
(B–D) Serum antibody reactivity with intact bacteria 14 days following immunization with heat-killed S. pneumoniae (as in [A]) assessed by
indirect immunofluorescence staining with flow cytometry analysis. Pooled serum from eight mice of each genotype was diluted in PBS and
incubated with heat-killed bacteria. (B) Reactivity of diluted sera (1:10–1000) from immunized mice. (C) Serum (diluted 1:10) was preincubated
with PPS-3 (400 g/ml final concentration; +PS) or PBS alone (−PS) for 20 min and then assessed for binding to bacteria. (D) Isotypes of
S. pneumoniae-specific antibodies in wild-type (thick solid line), CD19−/− (thin solid line), and hCD19Tg (dotted line) mouse serum diluted
1:10. Isotype-specific secondary antibodies were used to detect bound antibodies.
(E) PC-specific antibody responses in mice immunized with heat-killed S. pneumoniae as determined by ELISA using 3-fold serial dilutions
beginning at 1:100. Significant differences between mean (±SEM) titers are indicated by asterisks; *p < 0.05 (n R 5 mice per genotype).
(F) Survival of mice infected 14 days following immunization with S. pneumoniae (n = 6 mice/genotype for each challenge dose).
(G–H) Long-term protection of immunized mice against S. pneumoniae infection. (G) Survival of mice (6–7 per group) following S. pneumoniae
challenge 10 weeks after immunization with whole heat-killed bacteria. (H) Bacteria-reactive antibody 10 weeks post immunization with 107
heat-killed WU2 assessed by flow cytometry. Staining with secondary antibody alone is indicated by dashed lines.Immunization Provides Long-Lasting Protection t
1in CD19−/− Mice, but Not in hCD19Tg Mice
To determine if whole bacteria immunization induced i
mprotective antibodies, CD19−/−, wild-type, and hCD19Tg
mice were immunized with heat-killed bacteria. Four- ween days later, the mice were challenged with 103 or
04 cfu of bacteria, doses that resulted in 100% mortal-
ty in naive wild-type mice (data not shown). Prior im-
unization with whole bacteria protected CD19−/− and
ild-type mice from bacterial challenge (Figure 3F).
B-1a and B-1b Cells Have Unique Roles in Immunity
11However, only half of hCD19Tg mice were protected
from infection at a 104 cfu challenge dose. Thus, whole
bacteria immunizations induced lower protective anti-
body responses in hCD19Tg mice than in CD19−/− and
wild-type mice.
The duration of protective antibody responses was
assessed using mice that had been immunized once
with 107 heat-killed bacteria and had survived lethal
challenge as shown in Figure 3F. These mice were re-
challenged with 104 cfu 10 weeks after immunization.
Both CD19−/− and wild-type mice were equally pro-
tected during reinfection (Figure 3G). However, all
hCD19Tg mice succumbed to this secondary infection
by day 4 post challenge (p = 0.04, χ2 analysis; hCD19Tg
versus wild-type survival). The susceptibility of hCD19Tg
mice to reinfection correlated with their dramatic loss
of serum antibodies reactive with whole bacteria, while
wild-type and CD19−/− mice maintained antibodies re-
active with bacteria for at least 10 weeks post immuni-
zation (Figure 3H). Thus, protective humoral immune re-
sponses generated in CD19−/− and hCD19Tg mice were
qualitatively and quantitatively distinct.
CD19−/− and hCD19Tg Mice Have Distinct
B-1 Cell Subsets
Both CD19−/− and hCD19Tg mice have significantly re-
duced numbers of splenic B cells compared to wild-
type mice (Table 1), particularly B-2 cells as described
(Engel et al., 1995; Sato et al., 1995, 1997). CD19 defi-
ciency also impairs B-1a cell development in the
spleen, while CD19 overexpression favors B-1a cell de-
velopment (Engel et al., 1995; Rickert et al., 1995; Sato
et al., 1996). As a result, total spleen B-1a (CD5+B220+)
cell numbers were 78% lower in CD19−/− mice, while
B-1a cells were present at normal numbers in hCD19Tg
mice despite reduced numbers of B-2 cells (Table 1).
The frequency and number of peritoneal cavity B-2
(CD5−CD11b−B220+) cells were also significantly de-
creased in CD19−/− mice and hCD19Tg mice compared
to wild-type mice (Table 1).Table 1. B Lymphocyte Subsets in CD19−/− and hCD19Tg Mice
% of B220+ Lymphocytesa Lymphocyte Numbers (× 10−5)b % of Total Lymphocytes
Phenotypec CD19−/− Wild-Type hCD19Tg CD19−/− Wild-Type hCD19Tg CD19−/− Wild-Type hCD19Tg
Peritoneal Cavity
B-1a 2 ± 1* 14 ± 1 70 ± 3* 0.07 ± .02* 1.6 ± 0.2 5.6 ± 0.6* 1 ± 1* 10 ± 1 28 ± 2*
B-1b 58 ± 4* 40 ± 2 4 ± 1* 1.2 ± 0.2* 4.3 ± 0.6 0.3 ± 0.1* 27 ± 2 27 ± 1 2 ± 1*
B-2 39 ± 4 46 ± 4 25 ± 2* 1.0 ± 0.3* 4.3 ± 0.6 1.6 ± 0.2* 19 ± 2* 32 ± 3 10 ± 1*
B220+ 100 100 100 2.3 ± 0.5* 10 ± 0.1 8 ± 0.9 47 ± 2* 66 ± 2 40 ± 2*
Lymphocytes 4.7 ± 1.0* 15 ± 0.2 20 ± 0.2
Spleen
B-1a 4 ± 1* 8 ± 1 24 ± 3* 8 ± 2* 36 ± 2 31 ± 8 2.1 ± 0.1* 4.2 ± 0.4 7.0 ± 0.5*
B-2 80 ± 2 69 ± 1 40 ± 5* 165 ± 46* 326 ± 29 51 ± 12* 38 ± 3 39 ± 1 14 ± 1*
MZ 6 ± 1* 13 ± 2 12 ± 1 12 ± 2* 64 ± 14 16 ± 6* 3.2 ± 0.3* 7.3 ± 1.3 3.5 ± 0.5*
B220+ 100 100 100 206 ± 56* 472 ± 42 133 ± 38* 53 ± 4 55 ± 3 30 ± 2*
Lymphocytes 627± 141* 1,220 ± 44 713 ± 19*
*The percentage or number of cells was significantly different from that of wild type mice, *p < 0.05.
a Values represent the mean frequency (±SEM) of lymphocytes (based on side and forward angle light scatter) expressing the indicated
surface markers as determined by immunofluorescence staining with flow cytometry analysis. Results were from 3–12 mice of each genotype.
b Mean B cell numbers (±SEM) were calculated based on the total number of cells harvested from spleen or the peritoneal cavity.
c Cells were identified as follows: splenic B-2 cells, B220hiCD23+CD21int; splenic B-1a cells, B220+CD5+; MZ B cells, B220+CD1dhiCD21hi;
peritoneal B-2, B220+CD11b−CD5−; peritoneal B-1a, B220+CD11b+CD5+; and peritoneal B-1b cells, B220+CD11b+CD5−.The frequencies of peritoneal B-1a and B-1b cells
were clearly different between CD19−/−, wild-type, and
hCD19Tg mice when CD5 expression was used to dif-
ferentiate peritoneal B-1a (CD5+CD11b+) and B-1b
(CD5−CD11b+) cells. Although the peritoneal CD11b+ B
cell population exhibited an IgMhi phenotype in all
mice, the vast majority of CD11b+B220+ cells were
CD5− in CD19−/− mice, while the majority of B-1 cells in
hCD19Tg mice coexpressed CD5 (Table 1; Figure 4A).
In wild-type mice, w30% of CD11b+B220+ cells coex-
pressed CD5. In CD19−/− mice, the frequency of B-1b
cells among total peritoneal B220+ cells was signifi-
cantly higher than in wild-type mice (58% ± 4% versus
40% ± 2%; Table 1). By contrast, the number and fre-
quency of B-1a cells was 3- to 5-fold higher in hCD19Tg
mice than wild-type mice, whereas the number and fre-
quency of B-1b cells was R90% lower (Table 1). More-
over, the few CD11b+B220+ cells that appeared CD5−
in hCD19Tg mice actually expressed CD5 at densities
(mean fluorescence intensity values) that were w2-fold
higher (p < 0.05) than CD5−CD11b+B220+ cells from
wild-type or CD19−/− mice (data not shown). Thus, the
majority of peritoneal B-1 cells in hCD19Tg mice exhibit
a B-1a phenotype, while the majority of B-1 cells in
CD19−/− mice exhibit a B-1b phenotype.
MZ B Cell Development in CD19−/−
and hCD19Tg Mice
In CD19−/− mice, MZ B cell numbers and frequencies
were significantly reduced (81% and 54%, respectively;
Table 1, Figure 4B) as described for different lines of
CD19−/− mice (Makowska et al., 1999; Wang et al., 2002).
Although the frequency of MZ B cells among B220+
cells (12%–13%) was similar between hCD19Tg and
wild-type mice (Figure 4B), total spleen B cell numbers
were significantly reduced in hCD19Tg mice (Table 1).
As a result, MZ B cell numbers were also significantly
lower (w75% reduced) in hCD19Tg mice compared to
wild-type mice (Table 1). Immunohistochemical analysis
of spleen tissue sections from CD19−/− and hCD19Tg
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12Figure 4. B-1 and MZ B Cell Subsets in CD19−/−, Wild-Type, and hCD19Tg Mice
(A) Three-color staining of peritoneal B cells for B220, CD11b, and CD5 expression with flow cytometry analysis. B-1 (B220+CD11b+) and B-2
(B220+CD11b−) lymphocytes are indicated (left column) with histograms showing CD5 expression by peritoneal B-1 (B220+CD11b+-gated)
cells (right column). Isotype-matched control antibody staining is indicated by a dotted line.
(B) Frequencies of CD21hiCD1dhi MZ B cells among the B220+-gated spleen cell population.
(C) Immunohistochemical analysis of spleen sections. Upper sections were stained for CD23 (brown) and IgM (blue). Lower sections were
stained for CD1d (red) and B220 (green), with CD1dhiB220+ cells characterized by yellow fluorescence in overlaid digital microscopy images.
Original magnification: 200×. All results represent those obtained with R3 mice of each genotype.mice confirmed these results. In wild-type mice, an p
aIgMbright population of cells surrounded CD23bright
follicles, or a distinct B220+CD1dbright rim of MZ B cells c
psurrounded follicles (Figure 4C). However, only a thin
rim of CD23dull/−IgMbright cells was identified in spleen w
osections of CD19−/− mice, while a region of B220+
CD1dbright MZ cells was difficult to discern (Figure 4C). h
eAn organized MZ-like region of CD23dull/−IgMbright cells
or B220+CD1dbright staining was not identifiable in r
ohCD19Tg mice, consistent with their significant reduc-
tion in MZ B cell numbers (Table 1) and overall reduced i
3IgM expression (Engel et al., 1995; Rickert et al., 1995;
Sato et al., 1995, 1996, 1997). In addition, the MZs of p
tCD19−/− and hCD19Tg mice were insufficient to capture
complement-tagged antigens entering the spleen via 1
rthe blood unlike wild-type mice, as assessed using
C3dg-SA-PE tetramer complexes (data not shown) a
5(Haas et al., 2002). Thus, both CD19 deficiency and
CD19 overexpression impair splenic MZ B cell devel- c
Popment.
w
aB-1a Cells Produce Natural Antibody
pReactive with S. pneumoniae
To determine if B-1a cell deficiency in CD19−/− mice
explained their inability to generate natural serum anti- B
Abody reactive with S. pneumoniae (Figures 1B–1D),
peritoneal and splenic B-1a cells were transferred into T
dRag1−/− mice and assessed for their ability to spontane-
ously produce PPS-3-reactive antibody. Since hCD19Tg t
(mice exhibit an expanded B-1a cell population, theeritoneal cavity and spleens of these mice were used
s a source of B-1a (CD5+CD11b+B220+) cells. B-1a
ells represented w34% of the peritoneal cavity lym-
hocytes used for adoptive transfer (Figure 5A),
hereas CD5−CD11b−B220+ cells comprised onlyw1%
f lymphocytes (data not shown). Transfer of peritoneal
CD19Tg B cells into Rag1−/− mice resulted in the gen-
ration of serum immunoglobulin, including PPS-3-
eactive natural antibodies (Figure 5B). Likewise, transfer
f purified splenic B-1a cells into Rag1−/− mice resulted
n the generation of serum immunoglobulin and PPS-
-reactive natural antibodies (Figure 5B). Comparable
eritoneal B cell numbers were recovered from mice
hat had received hCD19Tg peritoneal cells (1.5 ± 0.5 ×
05) or spleen B-1a cells (1.5 ± 0.9 × 105). Furthermore,
ecovered peritoneal (CD19+) B cells coexpressed CD5
nd CD11b, indicating their B-1a phenotype (Figure
C). However, Rag1−/− mice that had received B-1a
ells from hCD19Tg mice did not significantly augment
PS-3 reactive antibody levels following immunization
ith PPS-3 (Figure 5D). Thus, B-1a cells are primarily
source of natural antibodies that may contribute to
rotection against S. pneumoniae infection.
-1b Cells from CD19−/− Mice Generate Adaptive
ntibody Responses to PPS-3
o determine if differences in B-1 subsets explained the
ramatic differences in PPS-3 antibody responses be-
ween CD19−/− and hCD19Tg mice, peritoneal B-1b
CD5−CD11b+B220+) and B-2 (CD5−CD11b−B220+) cells
B-1a and B-1b Cells Have Unique Roles in Immunity
13Figure 5. Peritoneal and Splenic B-1a Cells
Transferred into Rag1−/− Mice Produce PPS-
3-Reactive Natural Antibody
(A) Peritoneal cavity lymphocytes (5 × 106) or
FACS-purified splenic B-1a cells (CD5+B220+;
1 × 106) from hCD19Tg mice were transfer-
red i.p. into Rag1−/− mice (four mice/group).
(B) Total serum immunoglobulin (Ig; upper
graph) and PPS-3-reactive natural antibod-
ies (lower graph) in sera of Rag1−/− mice fol-
lowing adoptive transfers. Values represent
mean (±SEM) antibody titers from 3–4 mice/
group.
(C) B cell reconstitution in Rag1−/− mice 8
weeks following adoptive transfer. Peritoneal
cavity lymphocytes harvested from Rag1−/−
recipient mice were stained with antibodies
against mouse CD11b, CD5, and human
CD19 (hCD19) and analyzed by flow cyto-
metry. Percentages indicate mean (±SEM)
hCD19+CD11b+ cell frequencies for each re-
cipient group. Representative CD5 expres-
sion levels are shown for the hCD19+ and
hCD19− populations.
(D) PPS-3-specific IgM in Rag1−/− mice fol-
lowing adoptive transfer of hCD19Tg spleen
B cells and PPS-3 immunization. Ten weeks
following adoptive transfer, Rag1−/− mice
were immunized i.p. with 0.5 g PPS-3. PPS-
3-specific IgM levels were measured by
ELISA using serum samples diluted 1:25. Dif-
ferences between mean (±SEM) titers or OD
values of recipient and nonrecipient Rag1−/−
mice were significant; *p < 0.05 (n = 3–4
mice/group).from CD19−/− mice were purified (Figure 6A) and adop-
tively transferred into hCD19Tg mice. Spleen and lymph
node B cells from CD19−/− mice were also transferred
into hCD19Tg mice. Three weeks after cell transfer, the
hCD19Tg mice were immunized with PPS-3. IgM anti-
body responses to PPS-3 were present in mice that had
received peritoneal B-1b cells but not in mice that had
received peritoneal B-2 cells or spleen and lymph node
B cells (Figure 6B). Thus, peritoneal B-1b cells from
CD19−/− mice restored IgM responses to PPS-3 in
hCD19Tg mice.
B-1b Cells from Wild-Type Mice Generate
Adaptive Antibody Responses to PPS-3
Peritoneal B-1b cells from wild-type mice were also re-
sponsible for antibody responses to PPS-3. Spleen B
cells or peritoneal B-1a (CD5+CD11b+B220+) and B-1b
(CD5−CD11b+B220+) cells were purified from wild-type
mice (Figure 6C) and transferred into Rag1−/− mice.Four weeks after cell transfer, the mice were immunized
with PPS-3. Rag1−/− mice receiving B-1b cells gener-
ated anti-PPS-3 IgM responses that were significantly
higher than mice that had received B-1a cells, spleen
B cells, or no cells (Figure 6D). Importantly, analysis of
peritoneal B cells in Rag1−/− mice 8 weeks post transfer
demonstrated that R93% of peritoneal IgM+ cells from
B-1a, B-1b, and spleen B cell recipients expressed
CD11b, indicating that B-1 cells had primarily survived
and/or expanded within the peritoneal cavity following
adoptive transfer. The majority of IgM+ cells in B-1b re-
cipients were CD5− (80% ± 1%), while the majority of
IgM+ cells in B-1a recipients were CD5+ (60% ± 6%).
There was no significant difference in IgM+ cell num-
bers recovered from the peritoneum of B-1b recipients
(4.2 ± 1.4 × 104) or B-1a recipients (2.3 ± 0.3 × 104),
while there were 10-fold fewer peritoneal IgM+ cells in
mice that had received spleen B cells (4 ± 1 × 103).
Significant numbers of IgM+ cells were also recovered
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(A–B) Reconstituting hCD19Tg mice with peritoneal B-1b cells from CD19−/− mice initiates responsiveness to PPS-3. (A) Peritoneal B-1b
(CD5−CD11b+B220+) or B-2 (CD5−CD11b−B220+) cells from CD19−/− mice were isolated by FACS with the frequency of purified cells and CD5
expression indicated. (B) Purified peritoneal B cells or enriched spleen and lymph node B cells from CD19−/− mice were transferred i.p. into
hCD19Tg mice (105 cells/mouse). Mice were immunized with PPS-3 3 weeks later with PPS-3-specific antibody titers determined by ELISA
using 3-fold serial dilutions beginning at 1:25. Values represent mean (±SEM) titers obtained using R4 mice/group in two independent
adoptive transfer-immunization experiments.
(C–G) Reconstituting Rag1−/− mice with peritoneal B-1b cells from wild-type (WT) mice initiates responsiveness to PPS-3. (C) Peritoneal B-1a
(CD5+CD11b+B220+) or B-1b (CD5−CD11b+B220+) cells were purified from WT mice as described in (A). (D) Purified peritoneal B cells or
spleen B cells from WT mice were transferred into Rag1−/− mice by i.p. injection (105 cells/mouse). Mice were immunized with PPS-3 4 weeks
later, with PPS-3-specific antibody titers determined by ELISA using 3-fold serial dilutions beginning at 1:20. Results represent two independent
adoptive transfer experiments (CD5−CD11b+B220+, n = 6; CD5+CD11b+B220+, n = 5; Thy1.2− spleen cells, n = 3; and Rag1−/− no cell control, n =
3). (E–F) B-1b cells generate larger PPS-3-specific antibody responses than other B cell subsets. (E) MZ B cells (B220hiCD21hiCD1dhi) were
purified by FACS with the frequency of purified cells indicated. (F) MZ B (E) and unfractionated lymph node cells from WT mice were
transferred i.v. into Rag1−/− mice (105 B cells/mouse). Purified peritoneal B-1b cells were transferred into Rag1−/− mice by i.p. injection (105 B
cells/mouse). Mice were immunized with 0.5 g PPS-3 2 days later, with PPS-3-specific antibody levels determined by ELISA using serum
samples diluted 1:25. (B, D, and F) Differences between mean (±SEM) titers or OD values of recipient and nonrecipient mice were significant;
*p < 0.05 (n R 3 mice/group). (G) Purified WT peritoneal B-1a cells, B-1b cells, or unfractionated spleen or LN cells were transferred i.p. or
i.v. into Rag-1−/− mice (4 × 105 B cells/mouse; R3 mice/group) as indicated. Mice were immunized with 0.5 g PPS-3 3 days later, with PPS-
3-specific IgM (d7) and IgG3 (d14) antibody levels measured by ELISA using serum samples diluted 1:20. Differences between mean (±SEM)
titers of immunized mice were significantly different from nonimmunized mice receiving lymph node cells; *p < 0.05.
(H) B-1b cells provide protection during S. pneumoniae infection. Rag1−/− mice were given 4 × 105 purified WT peritoneal B-1b cells i.p (n =
5) or no cells (n = 7). Mice were immunized with 0.5 g PPS-3 3 days later. Mice were infected with 102 cfu S. pneumoniae 14 days
postimmunization. *Chi-square analysis indicates survival was significantly different between groups.
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15from the spleens of mice that had received peritoneal
B-1b (13 ± 4 × 104), B-1a (7 ± 1 × 104), and spleen (4 ±
1 × 104) B cells, but they were CD11b−. Thus, peritoneal
B-1a and B-1b cells from wild-type mice reconstituted
Rag1−/− mice to comparable degrees. However, PPS-3-
specific IgM responses were only found in mice recon-
stituted with B-1b cells.
The relative roles for peritoneal B-1a, B-1b, MZ,
spleen, and lymph node B cells in PPS-3 responses
was also assessed using wild-type B cells in short-term
adoptive transfer experiments. Purified peritoneal B-1b
cells (105) were transferred i.p. into Rag1−/− mice.
B220hiCD1dhiCD21hi MZ B cells (105) or lymph node
lymphocytes containing 105 B cells were transferred i.v.
into Rag1−/− mice (Figure 6E). Two days later, the mice
were immunized with PPS-3. B-1b cell recipients pro-
duced rapid and robust anti-PPS-3 antibody responses,
whereas PPS-3-specific responses were insignificant in
MZ and lymph node B cell recipients (Figure 6F). The
absence of an antibody response was not due to an
absence of B cells since mice receiving MZ B cells con-
tained 2.7 ± 1.5 × 104 IgM+ cells, while mice receiving
lymph node cells had 2.2 ± 1.3 × 104 IgM+ spleen B
cells 21 days after transfer. To further verify these re-
sults, similar experiments were carried out using 4-fold
higher numbers of B-1a, B-1b, spleen, or lymph node
cells given i.p. and/or i.v. Significant IgM and IgG3 PPS-
3-specific antibody responses were rapidly generated
in Rag1−/− mice reconstituted with B-1b cells, but not
in Rag1−/− mice reconstituted with peritoneal B-1a,
spleen, or lymph node cells (Figure 6G). Intravenous
transfers of 10-fold higher numbers of lymph node B
cells (106/mouse) into Rag1−/− mice increased PPS-
specific antibody levels after immunization, but 4 ± 2 ×
103 CD5−CD11b+IgMhi cells were found in the perito-
neal cavities, but not spleens, of these Rag1−/− mice
(data not shown). Similarly, i.p. transfers of higher num-
bers of spleen B cells depleted of CD21hiCD1dhi MZ B
cells (5 × 106/mouse) resulted in significant PPS-spe-
cific antibody levels following immunization at 5 weeks
post cell transfer, but 6 ± 1 × 104 CD5−CD11b+IgMhi B
cells were found in the peritoneal cavities, but not
spleens, of these Rag1−/− mice (data not shown). Thus,
B-1b cells or B-1b cell precursors in lymph nodes and
spleen may also contribute to PPS-specific antibody
responses. Although these experiments do not elimi-
nate a role for B-2 cells in PPS-3 antibody responses,
they demonstrate that B-1b cells are primarily responsi-
ble for the rapid and robust PPS-3 responses neces-
sary for protection against S. pneumoniae infection.
Wild-Type B-1b Cells Provide Protection
during S. pneumoniae Infection
To determine if B-1b cells provide protection during
S. pneumoniae infection, Rag1−/− mice were reconstitu-
ted with wild-type B-1b cells and immunized with PPS-
3. Two weeks later, the mice were challenged with a
lethal dose (102 cfu) of S. pneumoniae. Remarkably,
Rag1−/− mice reconstituted with B-1b cells were signifi-
cantly protected from infection compared to nonrecon-
stituted mice (Figure 6H). Thus, B-1b cells can provide
significant protection during S. pneumoniae infection.Discussion
This study reveals an unanticipated equilibrium be-
tween B-1a and B-1b cell development in wild-type
mice that balances innate and adaptive humoral im-
mune responses during S. pneumoniae infection. Spe-
cifically, B-1a cells from wild-type or hCD19Tg mice
were important for natural antibody production, while
B-1b cells from wild-type or CD19−/− mice functioned
independently to regulate protective anti-PPS responses
to S. pneumoniae. In addition, the B-1b subset was re-
quired for generating long-lasting protective responses
to S. pneumoniae, as recently shown for Borrelia herm-
sii immunity (Alugupalli et al., 2004). While this division
of labor was unanticipated, equally unexpected was
the finding that reciprocal alterations in CD19 expres-
sion differentially regulated the balance between B-1a
and B-1b cell development and thereby the generation
of innate and adaptive antibody responses required for
protection against S. pneumoniae. CD19 deficiency im-
paired B-1a development and the production of protec-
tive natural antibody, while CD19 overexpression im-
paired B-1b development and adaptive responses to
PPS-3. Although there is evidence to suggest that
CD19 signaling activity is differentially regulated in B-1
subsets as compared to conventional B cells (Krop et
al., 1996; Sen et al., 2002), our studies do not address
a biochemical role for CD19 in the B cell activation
pathways elicited during responses to bacterial infec-
tion or reveal how CD19 balances the development or
homeostasis of the B-1a versus B-1b cell compart-
ments. However, they do demonstrate that alterations
in this single cell surface molecule have dramatic ef-
fects on natural and acquired antibody production by
differentially regulating the balance between B-1a and
B-1b cell development.
B-1a cells were primarily responsible for natural anti-
body production, which was conferred with adoptive
transfer of these cells. B-1 cells in hCD19Tg mice were
primarily B-1a cells, and these mice had normal to
augmented levels of natural antibodies and exhibited
normal resistance to acute S. pneumoniae infection.
However, hCD19Tg mice did not generate PPS-3-spe-
cific antibodies in response to PPS-3 or whole bacteria
immunizations. Furthermore, antibody responses to
whole bacteria were restricted to non-IgG3 isotypes
and only provided short-lived humoral immunity that
left hCD19Tg mice susceptible to infection. By con-
trast, B-1b cells were responsible for acquired antibody
responses to PPS-3, which were conferred with the
adoptive transfer of these cells. Because B-1 cells in
CD19−/− mice were primarily, if not exclusively, B-1b
cells, these mice were deficient in natural antibodies
and were thereby more susceptible to S. pneumoniae
infection in the absence of immunization or previous
exposure. However, CD19−/− mice generated robust
IgM and IgG3 antibody responses to PPS-3 and whole
bacteria immunizations, which rendered them resistant
to infection and led to long-lived humoral immunity.
Wild-type B-1b cells also significantly protected PPS-
3-immunized Rag1−/− mice during S. pneumoniae infec-
tion. The importance of having both B-1a and B-1b
subsets is exemplified by the results from wild-type
mice, which generate both natural and acquired PPS-3
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16antibody responses and are thus afforded the greatest w
level of protection against infection. Importantly, in na- b
ive hosts, B-1a cell-derived natural antibodies are par- B
ticularly essential for establishing a basal level of pro- a
tection during an infection. In the absence of natural
antibodies, the host may not be initially protected from s
death such that B-1b cells may not have the opportu- c
nity to respond to an infection. Thus, B-1a and B-1b a
cell compartments both have critical yet distinct roles c
in generating protective immunity to S. pneumoniae. t
The relationship between B cells that produce natural t
antibodies and those which produce antibody upon a
pathogen encounter has not been entirely clear (Baum- i
garth et al., 1999; Kenny et al., 1983; Masmoudi et al., a
1990). Likewise, the relationship between B-1a and B-1b i
cell development is unclear (Berland and Wortis, 2002; s
Hardy and Hayakawa, 2001; Herzenberg, 2000). How- P
ever, the current studies reveal distinct and nonredun- a
dant functional roles for B-1a and B-1b subsets during f
innate and adaptive immune responses to S. pneumo- o
niae infection, respectively. These findings demonstrate d
that the B-1b cell subset that is induced to respond to u
PPS may be fundamentally different from the B-1a cell i
subset that produces natural antibodies reactive with t
PPS. Moreover, these two subsets may require different f
signals or signaling thresholds for their development, a
activation, and/or differentiation into antibody-produc- s
ing cells. In agreement with these proposals, others f
have suggested that B cells which produce antigen- o
reactive natural antibody before antigen encounter are g
distinct from the B cells that participate in acquired im- a
mune responses to antigen (Baumgarth et al., 1999). In s
contrast to our findings, a recent study demonstrated d
a correlation between the absence of B-1a cells and 2
poor responsiveness to PPS (Wardemann et al., 2002). s
Moreover, this study reported that fetal liver, but not d
adult bone marrow, cells reconstituted PPS responses i
in immunodeficient mice. Although the antibody re- i
sponse was interpreted to be due to fetal liver-derived p
B-1a cells, it is entirely possible that fetal B-1b cells c
produced the PPS-specific antibody. Indeed, the cur- f
rent study and other studies indicate that the B-1b cell v
subset is important for antibody responses to PPS and t
other clinically relevant TI antigens (Alugupalli et al., e
2004; Ohdan et al., 2000). s
B-1 and MZ B cells are proposed to provide protec- f
tion during early responses against TI blood-borne par- f
ticulate antigens through natural antibody production v
and antibody responses to TI-2 antigens (Martin and
Kearney, 2000; Martin et al., 2001). However, MZ B cells E
did not produce anti-PPS-3 responses in the adoptive
Mtransfer experiments performed in this study. In addi-
Ction, treatments that preferentially deplete MZ B cells,
ebut not B-1b cells, have no effect on PPS-3-specific
h
antibody responses in wild-type mice (K.M.H. and 7
T.F.T., unpublished data). Nonetheless, MZ B and B-1a (
cells may be important for responses against other TI (
wbacterial antigens, such as PC. In support of this,
mhCD19Tg mice generated PC-specific natural antibod-
iies as well as an IgM anti-PC response following whole
sbacteria immunization, while CD19−/− mice did not.
These findings highlight a clear and fascinating differ- A
ence between the factors that are required for anti-PPS B
aresponses compared to anti-PC responses, both ofhich contribute to protection during infection (Ams-
augh et al., 1972; Briles et al., 1981). Therefore, B-1a,
-1b, and MZ B cell subsets may play distinct roles in
ntibody responses to different TI bacterial antigens.
In summary, the production of acquired antibody re-
ponses against capsular polysaccharides by B-1b
ells and natural antibody by B-1a cells links innate and
daptive humoral immune responses necessary for
omplete protection against S. pneumoniae. Since al-
erations in CD19 expression affected the balance be-
ween B-1a cell-generated natural antibody production
nd B-1b cell-generated adaptive antibody responses
n such a significant way, it is likely that alterations in
dditional signaling pathways will have a similar potent
mpact. Altered signaling pathways, such as those re-
ulting from CD19 overexpression, may also regulate
PS-3 antibody responses by directly regulating B cell
ctivation or skewing the B cell repertoire, thereby af-
ecting the ability of B cells to respond to PPS-3 or
ther bacterial antigens. However, hCD19Tg mice pro-
uced natural antibodies reactive with PPS-3, yet were
nable to produce PPS-3-specific antibody following
mmunization. Thus, PPS-3-reactive B cells exist within
he hCD19Tg repertoire, but they were not expanded
ollowing bacterial challenge, presumably due to the
bsence of responding B-1b cells as proposed in this
tudy. Indeed, alterations in B-1 subset development or
unction due to deviations in B cell signaling pathways
r the other factors cited above may explain the hetero-
eneous responses of outbred populations to vaccines
nd their susceptibilities to infection. For example, the
kewed predominance of the B-1a cell subset early
uring development (Bhat et al., 1992; Herzenberg,
000) as well as the predominance of CD5+ B cells ob-
erved in patients with selective anti-polysaccharide
eficiency (Antall et al., 1999) may in part explain the
mpaired anti-polysaccharide responses and increased
ncidence of encapsulated bacterial infections in these
atients (Ortqvist, 2001). The global burden of pneumo-
occal disease creates an urgent need to delineate the
actors that influence susceptibility to infection and
accine efficacy. The current study provides an impor-
ant example of necessary factors that must be consid-
red in eliciting effective antibody responses to encap-
ulated bacteria such as S. pneumoniae. As such,
urther elucidation of B-1b subset development and




D19−/− and hCD19Tg (h19-1 line) mice were as described (Engel
t al., 1995; Sato et al., 1996, 1997; Zhou et al., 1994). CD19−/− and
CD19Tg mice were backcrossed with C57BL/6 mice for 14 and
generations, respectively. Wild-type C57BL/6 mice and Rag1−/−
B6.129S7-Rag1tm1Mom/J) mice were from The Jackson Laboratory
Bar Harbor, ME). Mice were used between 2–5 months of age and
ere housed under specific pathogen-free conditions. S. pneu-
oniae challenges were performed in a conventional animal facil-
ty. All studies and procedures were approved by the Duke Univer-
ity Animal Care and Use Committee.
ntibodies and Immunoflourescence Analysis
iotinylated- or fluorochrome-conjugated antibodies and second-
ry detection reagents used included: anti-mouse IgM or IgD
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17(Southern Biotechnology Associates, Inc., Birmingham, AL); anti-
human CD19 (B4, Beckman Coulter, Miami, FL); or antibodies re-
active with mouse CD21 (7G6), CD19 (ID3), B220 (RA3-6B2), CD23
(B3B4), CD5 (53-7.3), CD1d (1B1), and phycoerythrin (PE)- and
cychrome-conjugated streptavidin (all from BD-PharMingen). Sin-
gle cell lymphocyte suspensions from spleen and peritoneal cavity
were isolated and stained at 4°C for 25 min. Cells were analyzed
using a FACScan flow cytometer (Becton Dickinson, San Jose, CA),
with positive and negative cell populations determined using unre-
active isotype-matched antibodies (BD-Pharmingen).
Analysis of serum antibody binding to S. pneumoniae was car-
ried out by incubating heat-killed bacteria (107 cfu) with serum di-
luted in PBS for 30 min at room temperature, washing with PBS,
and detecting bound antibodies using PE-conjugated goat anti-
mouse immunoglobulin antibodies (Southern Biotechnology Asso-
ciates). 30,000 events were collected and analyzed per sample on
a FACScan flow cytometer.
Immunizations and S. pneumoniae Infections
All infections and whole bacteria immunizations used WU2, a type
3 strain of S. pneumoniae, as previously described (Haas et al.,
2002). For i.p. infections, bacteria were diluted in 200 l sterile PBS
with the number of cfus reconfirmed. Mice were immunized i.p.
with 0.5 g of PPS-3 (American Type Culture Collection, Rockville,
MD) or heat-killed (107 cfu) S. pneumoniae in PBS (Haas et al., 2002).
Enzyme-Linked Immunosorbent Assays
Enzyme-linked immunosorbent assays (ELISAs) used AP-conju-
gated polyclonal goat anti-mouse IgM and IgG3 antibodies (South-
ern Biotechnology Associates). PPS-3-specific and PC-specific an-
tibody titers were measured by adding serum samples to plates
coated with 10 g/ml PPS-3 in PBS or PC-BSA (Biosearch Technol-
ogies, Novato, CA) in 0.1 M borate-buffered saline overnight at 4°C.
ELISAs to detect S. pneumoniae-specific antibody were performed
as previously described (Haas et al., 2002). Endpoint titers were
determined using 3-fold serial serum dilutions and measured as the
reciprocal dilution yielding an OD405 value that was 3-fold higher
than that of the negative control OD with sera omitted.
Immunohistochemistry
Frozen spleen sections (5 m) mounted on gelatin-coated slides
were fixed in acetone, rehydrated in PBS, blocked in 5% normal
rabbit serum/2% bovine calf serum in PBS and reacted with biotin-
ylated CD23 antibody (BD-Pharmingen) in 2% bovine calf serum in
PBS. Sections were washed and incubated with streptavidin-HRP
(Southern Biotechnology Associates) and developed with 3, 3#-dia-
minobenzidine substrate (Vector Laboratories, Burlingame, CA).
AP-conjugated goat anti-mouse IgM antibody (Southern Biotech-
nology Associates) was used in conjunction with Vector blue AP
substrate kit (Vector Laboratories). Fluorescence immunohisto-
chemistry was performed following the acetone fix and blocking
steps as described above. Sections were incubated with PE-conju-
gated anti-CD1d and FITC-conjugated anti-B220, washed, and an-
alyzed using a fluorescence microscope.
Cell Sorting and Adoptive Transfers
B cell subsets were purified from peritoneal cavity or spleen lym-
phocytes using a FACSVantage SE flow cytometer (Becton-Dickin-
son) with purities of w85%–95%. Alternatively, spleen or lymph
node cell suspensions were enriched for B cells by Thy1.2-mag-
netic bead (Dynal, Lake Success, NY) depletion of T cells, with B
cell purities R90%. After isolation, the cells were immediately
transferred i.p. or i.v. into hCD19Tg or Rag1−/− mice.
Statistical Analysis
Data are shown as means ± SEM. Differences between sample
means were assessed using Student’s t test. Differences in survival
were assessed using Fisher’s exact test and Chi-square analysis.
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